Gaps in Mycosis Fungoides-Cutaneous T-Cell Lymphoma: Early Detection, Diagnosis, and Treatment

Release Date :
March 05, 2018
Expiration Date :
March 05, 2019
CLINICAL COMMENTARY FACULTY

Larisa Geskin, MD, FAAD
Associate Professor of Dermatology and Medicine
Director
Comprehensive Cutaneous Oncology Center
Columbia University
New York, New York

PROGRAM OVERVIEW

Mycosis fungoides (MF) is a rare, cutaneous T-cell lymphoma (MF-CTCL) which presents lifelong management challenges. Although the prognosis for advanced disease is poor, for the majority of patients who present with early-stage disease, a number of efficacious treatment options are available. However, early-stage MF-CTCL still provides a significant challenge for clinicians. Due to the rare nature of this disease, clinicians are often not familiar with the presentation of MF-CTCL and an accurate diagnosis is frequently delayed, as early-stage MF-CTCL mimics a number of common cutaneous diseases.

TARGET AUDIENCE

This educational initiative has been designed for dermatologists, dermatology oncologists, oncologists, dermatology nurses, advanced practitioners, pharmacists, and healthcare providers caring for patients with or suspected to have early-stage MF-CTCL.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

  • Describe signs and symptoms that should prompt suspicion of mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL)
  • Identify barriers to the accurate diagnosis of MF-CTCL and explain how such barriers may be effectively addressed
  • Outline an individualized approach to the treatment of early-stage MF-CTCL that includes appropriate use of skin-directed therapies for optimized patient care
DIRECTIONS TO THE LEARNER

There are no fees for participating and receiving CME credit for this enduring activity. During the period of March 5, 2018, through March 5, 2019, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 100%.

MEDIA

Internet

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported their financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Larisa Geskin, MD, FAAD

Consultant: Actelion, Bristol-Myers Squibb, Eisai, Innate, Kyowa, Medivir, Therakos
Speaker’s Bureaus: Actelion, Therakos
Research: Actelion, Bristol-Myers Squibb

Patima Tanapat, PhD, has no real or apparent conflicts of interest to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Actelion do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Integrity Continuing Education, Inc., and Actelion. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.

PRIVACY POLICY

When you participate in an online educational activity provided by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Firefox 2
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10

Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Firefox 2
Flash Player 10

Use of Internet Explorer browser is not recommended.

Click here for more information on minimum system requirements.

This CME activity is provided by Integrity Continuing Education.

This activity is jointly provided by Global Education Group and Integrity Continuing Education.

Supported by an educational grant from Actelion Pharmaceuticals US, Inc.

Continue to Pretest